Matinas BioPharma received a NYSE noncompliance notice for not holding its annual meeting

From GlobeNewswire: 2025-01-10 17:15:00

Matinas BioPharma Holdings, Inc. received a notice from NYSE American LLC due to not holding its annual meeting for the fiscal year ending on December 31, 2024. The company plans to hold the annual meeting by December 31, 2025 to regain compliance with NYSE American listing standards. Matinas BioPharma focuses on developing therapies using lipid nanocrystal platform delivery technology. Investors should be aware of risks and uncertainties related to the company’s product candidates. For more information, visit www.matinasbiopharma.com or contact CEO Jerome D. Jabbour at (908) 484-8805 or [email protected].



Read more at GlobeNewswire: Matinas BioPharma Receives NYSE Noncompliance Notice